Cargando…
Clinical Outcomes by Consolidation of Bone Marrow Stem Cell Therapy and Coronary Artery Bypass Graft in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-analysis
Bone marrow stem cell (BMSC) transplantation during coronary artery bypass graft (CABG) is an innovative treatment for ischemic heart disease (IHD). We conduct a meta-analysis to examine whether patients with IHD presenting heart failure with reduced ejection fraction (HFrEF) can be beneficent from...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932762/ https://www.ncbi.nlm.nih.gov/pubmed/36786355 http://dx.doi.org/10.1177/09636897231152381 |
_version_ | 1784889527005872128 |
---|---|
author | Jiang, Yinhao Yang, Ziying Shao, Lianbo Shen, Han Teng, Xiaomei Chen, Yihuan Ding, Yinglong Fan, Jiaming Yu, You Shen, Zhenya |
author_facet | Jiang, Yinhao Yang, Ziying Shao, Lianbo Shen, Han Teng, Xiaomei Chen, Yihuan Ding, Yinglong Fan, Jiaming Yu, You Shen, Zhenya |
author_sort | Jiang, Yinhao |
collection | PubMed |
description | Bone marrow stem cell (BMSC) transplantation during coronary artery bypass graft (CABG) is an innovative treatment for ischemic heart disease (IHD). We conduct a meta-analysis to examine whether patients with IHD presenting heart failure with reduced ejection fraction (HFrEF) can be beneficent from CABG with additional BMSC transplantation. Electronic searches were performed on PubMed, EMBASE, Cochrane Library, and ClinicalTrials.gov from their inception to July 2021. The efficacy was based on left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-diastolic volume (LVEDV), left ventricular end-diastolic volume index (LVEDVi), left ventricular end-systolic volume index (LVESVi), and 6-min walk test (6MWT) change after treatment. Eight randomized-controlled trials (RCTs) were included in this meta-analysis, with a total of 350 patients. Results showed BMSC transplantation significantly improved the LVEF [mean difference (MD) = 6.23%, 95% confidence interval (CI): 3.22%–9.24%, P < 0.0001], LVEDVi (MD = −20.15 ml/m(2), 95% CI: −30.49 to −9.82 ml/m(2), P < 0.00001), and LVESVi (MD = −17.69 ml/m(2), 95% CI: −25.24 to −10.14 ml/m(2), P < 0.00001). There was no statistically significant difference in the improvement of LVEDD, LVEDV, and 6MWT between the cell transplantation group and control groups. Subgroup analysis revealed that the intervention for control group could affect the efficacy of BMSC transplantation. Sensitivity analysis found the conclusion of LVEDD, LVEDV, and 6MWT changes was not stable. Therefore, among patients with IHD presenting HFrEF, BMSC transplantation during CABG is promising to be beneficial for postoperative left ventricular (LV) function improvement. However, according to the unstable results of the sensitivity analysis, it cannot be concluded whether the extra step has a positive effect on left ventricular remodeling and exercise capacity. RCTs with larger cohorts and more strict protocols are needed to validate these conclusions. |
format | Online Article Text |
id | pubmed-9932762 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-99327622023-02-17 Clinical Outcomes by Consolidation of Bone Marrow Stem Cell Therapy and Coronary Artery Bypass Graft in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-analysis Jiang, Yinhao Yang, Ziying Shao, Lianbo Shen, Han Teng, Xiaomei Chen, Yihuan Ding, Yinglong Fan, Jiaming Yu, You Shen, Zhenya Cell Transplant Original Article Bone marrow stem cell (BMSC) transplantation during coronary artery bypass graft (CABG) is an innovative treatment for ischemic heart disease (IHD). We conduct a meta-analysis to examine whether patients with IHD presenting heart failure with reduced ejection fraction (HFrEF) can be beneficent from CABG with additional BMSC transplantation. Electronic searches were performed on PubMed, EMBASE, Cochrane Library, and ClinicalTrials.gov from their inception to July 2021. The efficacy was based on left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-diastolic volume (LVEDV), left ventricular end-diastolic volume index (LVEDVi), left ventricular end-systolic volume index (LVESVi), and 6-min walk test (6MWT) change after treatment. Eight randomized-controlled trials (RCTs) were included in this meta-analysis, with a total of 350 patients. Results showed BMSC transplantation significantly improved the LVEF [mean difference (MD) = 6.23%, 95% confidence interval (CI): 3.22%–9.24%, P < 0.0001], LVEDVi (MD = −20.15 ml/m(2), 95% CI: −30.49 to −9.82 ml/m(2), P < 0.00001), and LVESVi (MD = −17.69 ml/m(2), 95% CI: −25.24 to −10.14 ml/m(2), P < 0.00001). There was no statistically significant difference in the improvement of LVEDD, LVEDV, and 6MWT between the cell transplantation group and control groups. Subgroup analysis revealed that the intervention for control group could affect the efficacy of BMSC transplantation. Sensitivity analysis found the conclusion of LVEDD, LVEDV, and 6MWT changes was not stable. Therefore, among patients with IHD presenting HFrEF, BMSC transplantation during CABG is promising to be beneficial for postoperative left ventricular (LV) function improvement. However, according to the unstable results of the sensitivity analysis, it cannot be concluded whether the extra step has a positive effect on left ventricular remodeling and exercise capacity. RCTs with larger cohorts and more strict protocols are needed to validate these conclusions. SAGE Publications 2023-02-14 /pmc/articles/PMC9932762/ /pubmed/36786355 http://dx.doi.org/10.1177/09636897231152381 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Article Jiang, Yinhao Yang, Ziying Shao, Lianbo Shen, Han Teng, Xiaomei Chen, Yihuan Ding, Yinglong Fan, Jiaming Yu, You Shen, Zhenya Clinical Outcomes by Consolidation of Bone Marrow Stem Cell Therapy and Coronary Artery Bypass Graft in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-analysis |
title | Clinical Outcomes by Consolidation of Bone Marrow Stem Cell Therapy
and Coronary Artery Bypass Graft in Patients With Heart Failure With Reduced
Ejection Fraction: A Meta-analysis |
title_full | Clinical Outcomes by Consolidation of Bone Marrow Stem Cell Therapy
and Coronary Artery Bypass Graft in Patients With Heart Failure With Reduced
Ejection Fraction: A Meta-analysis |
title_fullStr | Clinical Outcomes by Consolidation of Bone Marrow Stem Cell Therapy
and Coronary Artery Bypass Graft in Patients With Heart Failure With Reduced
Ejection Fraction: A Meta-analysis |
title_full_unstemmed | Clinical Outcomes by Consolidation of Bone Marrow Stem Cell Therapy
and Coronary Artery Bypass Graft in Patients With Heart Failure With Reduced
Ejection Fraction: A Meta-analysis |
title_short | Clinical Outcomes by Consolidation of Bone Marrow Stem Cell Therapy
and Coronary Artery Bypass Graft in Patients With Heart Failure With Reduced
Ejection Fraction: A Meta-analysis |
title_sort | clinical outcomes by consolidation of bone marrow stem cell therapy
and coronary artery bypass graft in patients with heart failure with reduced
ejection fraction: a meta-analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932762/ https://www.ncbi.nlm.nih.gov/pubmed/36786355 http://dx.doi.org/10.1177/09636897231152381 |
work_keys_str_mv | AT jiangyinhao clinicaloutcomesbyconsolidationofbonemarrowstemcelltherapyandcoronaryarterybypassgraftinpatientswithheartfailurewithreducedejectionfractionametaanalysis AT yangziying clinicaloutcomesbyconsolidationofbonemarrowstemcelltherapyandcoronaryarterybypassgraftinpatientswithheartfailurewithreducedejectionfractionametaanalysis AT shaolianbo clinicaloutcomesbyconsolidationofbonemarrowstemcelltherapyandcoronaryarterybypassgraftinpatientswithheartfailurewithreducedejectionfractionametaanalysis AT shenhan clinicaloutcomesbyconsolidationofbonemarrowstemcelltherapyandcoronaryarterybypassgraftinpatientswithheartfailurewithreducedejectionfractionametaanalysis AT tengxiaomei clinicaloutcomesbyconsolidationofbonemarrowstemcelltherapyandcoronaryarterybypassgraftinpatientswithheartfailurewithreducedejectionfractionametaanalysis AT chenyihuan clinicaloutcomesbyconsolidationofbonemarrowstemcelltherapyandcoronaryarterybypassgraftinpatientswithheartfailurewithreducedejectionfractionametaanalysis AT dingyinglong clinicaloutcomesbyconsolidationofbonemarrowstemcelltherapyandcoronaryarterybypassgraftinpatientswithheartfailurewithreducedejectionfractionametaanalysis AT fanjiaming clinicaloutcomesbyconsolidationofbonemarrowstemcelltherapyandcoronaryarterybypassgraftinpatientswithheartfailurewithreducedejectionfractionametaanalysis AT yuyou clinicaloutcomesbyconsolidationofbonemarrowstemcelltherapyandcoronaryarterybypassgraftinpatientswithheartfailurewithreducedejectionfractionametaanalysis AT shenzhenya clinicaloutcomesbyconsolidationofbonemarrowstemcelltherapyandcoronaryarterybypassgraftinpatientswithheartfailurewithreducedejectionfractionametaanalysis |